BRPI0618873A2 - polimorfos c e g purificados, formulação farmacêutica de suspensão e métodos para administrar 17-aag a um indivíduo e para preparar uma formulação farmacêutica, 17-aag purificada e o polimorfo c purificado de 17-aag - Google Patents

polimorfos c e g purificados, formulação farmacêutica de suspensão e métodos para administrar 17-aag a um indivíduo e para preparar uma formulação farmacêutica, 17-aag purificada e o polimorfo c purificado de 17-aag

Info

Publication number
BRPI0618873A2
BRPI0618873A2 BRPI0618873A BRPI0618873A BRPI0618873A2 BR PI0618873 A2 BRPI0618873 A2 BR PI0618873A2 BR PI0618873 A BRPI0618873 A BR PI0618873A BR PI0618873 A BRPI0618873 A BR PI0618873A BR PI0618873 A2 BRPI0618873 A2 BR PI0618873A2
Authority
BR
Brazil
Prior art keywords
aag
purified
pharmaceutical formulation
polymorph
polymorphs
Prior art date
Application number
BRPI0618873A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Redvers Eberlin
Greg O Buchanan
Jorge Galazzo
Peter J Licari
Robert Arslanian
Ruchir P Desai
Stephen William Watt
Timothy Leaf
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of BRPI0618873A2 publication Critical patent/BRPI0618873A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0618873A 2005-11-23 2006-11-16 polimorfos c e g purificados, formulação farmacêutica de suspensão e métodos para administrar 17-aag a um indivíduo e para preparar uma formulação farmacêutica, 17-aag purificada e o polimorfo c purificado de 17-aag BRPI0618873A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73922505P 2005-11-23 2005-11-23
US80952706P 2006-05-30 2006-05-30
US11/595,005 US7648976B2 (en) 2005-11-23 2006-11-08 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
PCT/US2006/044746 WO2007061878A2 (en) 2005-11-23 2006-11-16 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations

Publications (1)

Publication Number Publication Date
BRPI0618873A2 true BRPI0618873A2 (pt) 2016-09-06

Family

ID=38067791

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618873A BRPI0618873A2 (pt) 2005-11-23 2006-11-16 polimorfos c e g purificados, formulação farmacêutica de suspensão e métodos para administrar 17-aag a um indivíduo e para preparar uma formulação farmacêutica, 17-aag purificada e o polimorfo c purificado de 17-aag

Country Status (8)

Country Link
US (1) US7648976B2 (enExample)
EP (1) EP1951223A4 (enExample)
JP (1) JP2009517386A (enExample)
KR (1) KR20080089357A (enExample)
AU (1) AU2006318771A1 (enExample)
BR (1) BRPI0618873A2 (enExample)
CA (1) CA2629196A1 (enExample)
WO (1) WO2007061878A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
CA3030142A1 (en) * 2016-07-08 2018-01-11 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
EP1373215B1 (en) 2001-03-30 2006-07-26 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Geldanamycin derivatives useful for treating cancer
US20040138160A1 (en) 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
DE60225307T2 (de) 2001-09-24 2009-03-19 Conforma Therapeutics Corp., San Diego Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine
JP2005528390A (ja) 2002-04-10 2005-09-22 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン製剤およびその製造ならびに使用方法
US20060148776A1 (en) 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20050256097A1 (en) 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
WO2006034147A2 (en) 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20060067953A1 (en) 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
CA2596867A1 (en) 2005-02-28 2006-09-08 Kosan Biosciences Incorporated Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
US20060228405A1 (en) * 2005-04-07 2006-10-12 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same

Also Published As

Publication number Publication date
JP2009517386A (ja) 2009-04-30
EP1951223A2 (en) 2008-08-06
US20070203110A1 (en) 2007-08-30
AU2006318771A1 (en) 2007-05-31
CA2629196A1 (en) 2007-05-31
WO2007061878A3 (en) 2009-06-04
EP1951223A4 (en) 2010-04-21
US7648976B2 (en) 2010-01-19
WO2007061878A2 (en) 2007-05-31
KR20080089357A (ko) 2008-10-06

Similar Documents

Publication Publication Date Title
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0817907A8 (pt) aparelho para administrar uma substância a um indivíduo
DK3719018T3 (da) Purin og deazapurinderivater som farmaceutiske forbindelser
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
BR122020011920A2 (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
BRPI0811267A2 (pt) Variante de fenilanina amônia-liase procariótica, composição farmacêutica, método para o tratamento de uma doença, uso de uma variante de fenilalanina amônia-liase procariótica, método para o tratamento de uma condição, e, variante de fenilalanina amônia-liase de anabaena variabilis.
BRPI0810439A2 (pt) Formulações farmacêuticas contendo derivados de ácido lipóico
BRPI0905680A2 (pt) "composição farmacêutica de uma composição farmacêutica"
BRPI0816320A2 (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
BRPI0919578A2 (pt) produto, composto, e processos para o isolamento de um composto e para a preparação de dronedarona ou um sal do mesmo, de uma formulação farmacêutica compreendendo dronedarona ou um sinal do mesmo e de um intermediário de dronedarona ou um sal do mesmo
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
PL1874746T3 (pl) Pochodne 1-N-azacykloalkilo-3-fenoksypropanu użyteczne do wytwarzania leków psychotropowych
IL204126A (en) Derivatives of 1, 3 - dihydroisoindole, their preparation, use, drugs and kit containing them and intermediates
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
IL188856A0 (en) Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20080077058/RJ DE 21/05/2008.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B11M Dismissal: decision cancelled

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]